Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2025, Quick Ratio deteriorated to 2.04 below Scisparc Ltd's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 311 other companies have achieved higher Quick Ratio than Scisparc Ltd in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from to 1450.

Explain Quick Ratio?
How much Cash & cash equivalents SPRC�s has?
What are SPRC�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/SPRC/financial-strength

https://api.csimarket.com/api/v1/companies/SPRC/fundamentals

https://api.csimarket.com/api/v1/companies/SPRC/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

SPRC Quick Ratio	(Dec 31 2025) Q4	0 Q3	0 Q2	0 Q1	(Dec 31 2024) Q4
Y / Y Current Liabilities Change	999.02 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	198.12 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	2.04	Subscribe	Subscribe	Subscribe	Subscribe
SPRC's Total Ranking	# 1450	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	0 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	0 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio fourth quarter 2025 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 312
Healthcare Sector	# 542
Overall Market	# 1450

Quick Ratio Statistics
High	Average	Low
286.06	18.58	0.56
(Dec 31 2020)		(Jun 30 2019)

Financial Statements
Scisparc Ltd's Current Liabilities	$ 2 Millions	Visit SPRC's Balance sheet
Scisparc Ltd's Cash & cash equivalent	$ 5 Millions	Visit SPRC's Balance sheet
Source of SPRC's Sales		Visit SPRC's Sales by Geography

Cumulative Scisparc Ltd's Quick Ratio

SPRC's Quick Ratio for the trailling 12 Months

SPRC Quick Ratio	(Dec 31 2025) 12 Months	0 12 Months	0 12 Months	0 12 Months	(Dec 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	143.65 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	157.71 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	1.66	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 831	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	28.55 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	24.87 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to SPRC Financial Strength Comparisons >> Go to Compare SPRC Quick Ratio to its Competitors

On the trailing twelve months basis Due to unchanged in Current Liabilities in the Q4 2025 to $2.25 millions, cumulative Quick Ratio decreased to 1.66 below the Scisparc Ltd average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 482 other companies have achieved higher Quick Ratio than Scisparc Ltd. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from to 3065.

Explain Quick Ratio?
How much Cash & cash equivalents SPRC�s has?
What are SPRC�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 483
Healthcare Sector	# 980
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
8.6	2.37	0.33
(Dec 31 2020)		(Dec 31 2018)

Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry	Quick Ratio	Dec 31 2025 MRQ Cash & cash equivalent	Dec 31 2025 MRQ Current Liabilities
Annexon Inc	5.59	$ 238.345 Millions	$ 42.630 Millions
Puretech Health Plc	5.59	$ 258.842 Millions	$ 46.309 Millions
Oramed Pharmaceuticals Inc	5.55	$ 62.343 Millions	$ 11.223 Millions
Zenas Biopharma Inc	5.48	$ 343.192 Millions	$ 62.649 Millions
Revelation Biosciences Inc	5.35	$ 10.700 Millions	$ 1.998 Millions
Talphera Inc	5.35	$ 20.381 Millions	$ 3.809 Millions
Compass Pathways Plc	5.34	$ 149.987 Millions	$ 28.079 Millions
Abivax Sa	5.29	$ 606.382 Millions	$ 114.655 Millions
Biomea Fusion Inc	5.24	$ 55.812 Millions	$ 10.647 Millions
Obsidian Therapeutics, Inc.	5.24	$ 80.486 Millions	$ 15.362 Millions
Matinas Biopharma Holdings Inc	5.21	$ 3.999 Millions	$ 0.767 Millions
United Therapeutics Corporation	5.21	$ 2,920.300 Millions	$ 560.600 Millions
Silence Therapeutics Plc	5.20	$ 85.114 Millions	$ 16.359 Millions
Palvella Therapeutics Inc	5.11	$ 57.982 Millions	$ 11.344 Millions
Transcode Therapeutics Inc	5.10	$ 17.814 Millions	$ 3.494 Millions
Enveric Biosciences Inc	5.09	$ 4.677 Millions	$ 0.918 Millions
Assembly Biosciences Inc	5.09	$ 248.106 Millions	$ 48.780 Millions
Nucana Plc	5.06	$ 32.610 Millions	$ 6.445 Millions
Atossa Therapeutics Inc	5.02	$ 41.409 Millions	$ 8.255 Millions
Lyell Immunopharma Inc	5.00	$ 247.220 Millions	$ 49.412 Millions
Sionna Therapeutics Inc	4.99	$ 58.451 Millions	$ 11.712 Millions
Sensei Biotherapeutics Inc	4.98	$ 21.184 Millions	$ 4.251 Millions
Kiora Pharmaceuticals Inc	4.93	$ 17.089 Millions	$ 3.467 Millions
Zevra Therapeutics Inc	4.86	$ 191.011 Millions	$ 39.277 Millions
Rafael Holdings Inc	4.85	$ 52.769 Millions	$ 10.877 Millions
Catalyst Pharmaceuticals Inc	4.82	$ 709.171 Millions	$ 147.152 Millions
Cytokinetics Incorporated	4.81	$ 882.221 Millions	$ 183.341 Millions
Nervgen Pharma Corp	4.74	$ 16.095 Millions	$ 3.397 Millions
Inmed Pharmaceuticals Inc	4.73	$ 6.998 Millions	$ 1.480 Millions
Maravai Lifesciences Holdings Inc	4.72	$ 216.890 Millions	$ 45.917 Millions

Date modified: 2026-07-07T13:49:59+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.